Literature DB >> 7815522

Encapsidation and serial passage of a poliovirus replicon which expresses an inactive 2A proteinase.

D C Ansardi1, R Pal-Ghosh, D Porter, C D Morrow.   

Abstract

The multiple roles of the viral proteinase 2A in poliovirus replication have been difficult to assess because, to date, it has not been possible to isolate and characterize a viral genome with an inactive 2Apro. We have previously reported that a poliovirus replicon containing an inactive 2Apro by virtue of a change at amino acid 109 from a cysteine to a serine (C109S) was replication competent when transfected into cells previously infected with vaccinia virus (R. Pal-Ghosh and C. D. Morrow, J. Virol. 67:4621-4629, 1993). To further develop this system, we have used a poliovirus replicon which contains the human immunodeficiency virus type 1 (HIV-1) gag gene positioned between nucleotides 1174 and 2470 of the poliovirus genome and have engineered a second mutation within this replicon to change the codon for amino acid 109 of the 2Apro from cysteine to serine (2AC109S). Transfection of this replicon into cells previously infected with vaccinia virus results in the replication and expression of a protein with a molecular mass consistent with that of a P1-HIV-1 Gag-2A fusion protein. Using a recently described complementation system which relies on the capacity of a recombinant vaccinia virus (VV-P1) to provide the capsid precursor (P1) in trans (D. C. Ansardi, D. C. Porter, and C. D. Morrow, J. Virol. 67:3684-3690, 1993; and D. C. Porter, D. C. Ansardi, W. S. Choi, and C. D. Morrow, J. Virol. 67:3712-3719, 1993), we have encapsidated this replicon containing the 2AC109S mutation. By using reverse transcription PCR, we demonstrated that after 15 serial passages the encapsidated replicon still contained the 2AC109S mutation. Infection of cells with a stock of encapsidated replicon, either in the presence or in the absence of vaccinia virus, resulted in the expression of the P1-HIV-1 Gag-2A fusion protein. Expression of the P1-HIV-1 Gag fusion protein in cells infected with the encapsidated replicon containing the 2AC109S mutation was reduced compared with the expression of P1-HIV-1 Gag in those cells infected with a replicon containing a wild type 2A gene. The protein expression and replication of the replicon RNA in cells containing the 2AC109S mutation was maintained for a longer period of time than for the replicons containing the wild-type 2A gene, possibly because of a reduced cytopathic effect.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7815522      PMCID: PMC188721     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

2.  Genetic complementation among poliovirus mutants derived from an infectious cDNA clone.

Authors:  H D Bernstein; P Sarnow; D Baltimore
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

3.  Primary structure, gene organization and polypeptide expression of poliovirus RNA.

Authors:  N Kitamura; B L Semler; P G Rothberg; G R Larsen; C J Adler; A J Dorner; E A Emini; R Hanecak; J J Lee; S van der Werf; C W Anderson; E Wimmer
Journal:  Nature       Date:  1981-06-18       Impact factor: 49.962

4.  Poliovirus-induced inhibition of host-cell protein synthesis.

Authors:  E Ehrenfeld
Journal:  Cell       Date:  1982-03       Impact factor: 41.582

5.  Systematic nomenclature of picornavirus proteins.

Authors:  R R Rueckert; E Wimmer
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

6.  Poliovirus proteinase 2A induces cleavage of eucaryotic initiation factor 4F polypeptide p220.

Authors:  H G Kräusslich; M J Nicklin; H Toyoda; D Etchison; E Wimmer
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

7.  Poliovirus polypeptide precursors: expression in vitro and processing by exogenous 3C and 2A proteinases.

Authors:  M J Nicklin; H G Kräusslich; H Toyoda; J J Dunn; E Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

8.  Poliovirus mutant that does not selectively inhibit host cell protein synthesis.

Authors:  H D Bernstein; N Sonenberg; D Baltimore
Journal:  Mol Cell Biol       Date:  1985-11       Impact factor: 4.272

9.  A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein.

Authors:  H Toyoda; M J Nicklin; M G Murray; C W Anderson; J J Dunn; F W Studier; E Wimmer
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

10.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

View more
  5 in total

1.  Strand-specific RNA synthesis defects in a poliovirus with a mutation in protein 3A.

Authors:  Natalya L Teterina; Mario S Rinaudo; Ellie Ehrenfeld
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

2.  Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity.

Authors:  S Tang; R van Rij; D Silvera; R Andino
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

3.  Genetic map of the calicivirus rabbit hemorrhagic disease virus as deduced from in vitro translation studies.

Authors:  C Wirblich; H J Thiel; G Meyers
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Picornavirus 2A protease regulates stress granule formation to facilitate viral translation.

Authors:  Xiaodan Yang; Zhulong Hu; Shanshan Fan; Qiang Zhang; Yi Zhong; Dong Guo; Yali Qin; Mingzhou Chen
Journal:  PLoS Pathog       Date:  2018-02-07       Impact factor: 6.823

5.  Viral cysteine proteinases.

Authors:  Alexander E Gorbalenya; Eric J Snijder
Journal:  Perspect Drug Discov Des       Date:  1996
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.